Nkarta Inc (NKTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.83 (+0.71%), Market cap $0.21B, 52-week low–high $1.66 ~ $3.49.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, Ca
Financial statements, price targets, institutional (13F) holdings and related news for Nkarta Inc are updated in real time on BlackAll Trade.
Nkarta Inc trades at $2.83 (+0.71%). Real-time quotes and charts are available on BlackAll Trade.
Nkarta Inc has a market cap of about $0.21B.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a